Ocular side effects associated with bisphosphonates

Drugs of Today

Volumn 39, Issue 11, 2003, Pages 829-835

  Fraunfelder, Frederick W ^a,b,c,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d CASEY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BLEPHARITIS; BLINDNESS; BONE METASTASIS; CANCER; CATARACT; CLINICAL TRIAL; COLOR VISION DEFECT; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CORNEA OPACITY; CRANIAL NERVE PARALYSIS; DIPLOPIA; DRUG MECHANISM; DRUG WITHDRAWAL; EPISCLERITIS; EXOPHTHALMOS; EYE DISEASE; EYE INFLAMMATION; EYE PAIN; EYELID EDEMA; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HETEROTOPIC OSSIFICATION; HUMAN; HYPERCALCEMIA; LACRIMAL GLAND DISEASE; MYDRIASIS; OPTIC NERVE DISEASE; ORBIT DISEASE; ORBIT EDEMA; OSTEOLYSIS; PAGET BONE DISEASE; PAPILLEDEMA; PERIORBITAL EDEMA; PHOTOPHOBIA; POSTMENOPAUSE; PTOSIS; RETINA DISEASE; RETROBULBAR OPTIC NEUROPATHY; REVIEW; SCLERITIS; TREATMENT INDICATION; UVEITIS; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; WORLD HEALTH ORGANIZATION;

DIPHOSPHONATES; FEMALE; HUMANS; SCLERITIS;

EID: 0347717760     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.11.799461     Document Type: Review

References (25)

1. Fleisch, H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991, 42: 919-44.
2. Montvale, N.J. Physicians' Desk Reference, vol. 56. Medical Economics 2002.
3. Fraunfelder, F.W., Rosenbaum, J.T. Drug-induced uveitis. Incidence, prevention and treatment. Drug Saf 1997, 17: 197-207.
4. Macarol, V., Fraunfelder, F.T. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994, 118: 220-4.
5. Fraunfelder, F.W., Fraunfelder, F.T. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2002, 135: 219-222.
6. Fraunfelder, F.W., Fraunfelder, F.T. Bisphosphonates and ocular side effects. N Engl J Med 2003, 348: 1187-8.
7. Foster, C.S., Forstot, S.L., Wilson, L.A. Mortality rate and rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis: Effects of systemic immunosuppression. Ophthalmology 1984, 91: 1253-63.
8. Watson, P.G. The nature and the treatment of scleral inflammation. Trans Ophthalmol Soc UK 1982, 102: 257-81.
9. Edwards, R., Biriell, C. Harmonisation in pharmacovigilance. Drug Safety 1994, 10: 93-102.
10. De, S., Meyer, P., Crisp, A.J. Pamidronate and uveitis (letter to the editor). Br J Ophthalmol 1995, 34: 479.
11. Siris, E.S. Bisphosphonates and iritis. Lancet 1993, 341: 436-7.
12. Stewart, G.O., Stuckey, B.G., Ward, L.C. Iritis following intravenous pamidronate. Aust N Z J Med 1996, 26: 414-5.
13. Robinson, J., Abood, E., Durham, B. The use of intravenous disodium pamidronate for the treatment of Paget's disease of bone. Paper presented at: First International Symposium on Paget's Disease of Bone, Manchester, UK, August 1992.
14. Ghose, K., Waterworth, R., Trolove, P. Uveitis associated with pamidronate. Aust N Z J Ophthalmol 1994, 24: 320.
15. Des Grottes, J.M., Schrooyen, M., Dumon, J.C. Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria. Clin Rheumatol 1997, 16: 93-5.
16. Morton, A.R. Disodium pamidronate for the management of single-dose versus daily infusions and infusion duration. In: Disodium pamidronate in the treatment of malignancy-related disorders. Hans Huber Publishers, Toronto 1989, 85-100.
17. Mbekeani, J.N., Slamovits T.L., Schwartz, B.H., Sauer, H.L. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999, 117: 837-8.
18. Malik, A.R., Campbell, S.H., Toma, N.M. Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 2002, 86: 1443.
19. Vinas, G., Olive, A., Holgado, S., Costa, J. Episcleritis secondary to risedronate. Med Clin 2002, 118: 598-9.
20. Diel, I.J., Solomayer, E.F., Costa, S.D. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339: 357-63.
21. Fietta, P., Manganelli, P., Lodigiani, L. Clodronate induced uveitis. Ann Rheum Dis 2003, 62: 378.
22. Delmas, P. Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: Results from a pivotal phase III study. Abstract presented at: World Congress on Osteoporosis, Lisbon, Portugal, May 2002.
23. Soerdjbalie-Maikoe, V., Pelger, R.C., Lycklama a Nijeholt, G.A. et al. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging 2002, 29: 494-8.
24. Martin, T.J., Grill, V. Bisphosphonate-mechanisms of action. Exp Clin Psycopharmacol 2003, 23: 130-2.
25. Thiebaud, D., Sauty, A, Burckhardt, P. et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997, 61: 386-92.